Introduction: Hepatitis C virus infects 3% people globally, that causes significant morbidity and mortality. For diagnosis and monitoring of treatment of HCV infection; biochemical markers and HCV RNA are tested. Aim of the Study: We tried to find out whether there is an association of liver enzymes (AST, ALT) and anti HCV antibody with the HCV viral load in patient's serum. Material and Methods: 238 consecutive patients with suspected or confirmed Hepatitis C viral disease were included in this study. All consecutive samples of patients for two years were tested for HCV RNA quantification using real time PCR (viral load). Serum aminotransferase (AST, ALT) and anti-HCV antibody levels were also recorded and compared with the viral load. Correlation coefficient was used to study association between different parameters. Results: Significant positive correlation was found between liver enzymes (AST, ALT) and HCV viral load. Conclusion: There is a significant correlation between liver enzymes and RNA viral load. Therefore, viral load may be substituted with test for liver enzymes during monitoring of treatment, at least partially, and this could result in substantial cost savings.
Introduction
H epatitis C virus (HCV) is the most common cause of liver disease, such as chronic hepatitis, cirrhosis, and hepatocellular carcinoma (HCC), leads to liver transplantation in many cases. [1] [2] [3] The mortality from HCV is predicted to increase as patients with HCV surviving for a longer duration. This greatly affects public health and leads to economic burden as well. Biochemical and viral markers detect the severity of liver disease and also help to monitor the patient response during treatment. Biochemical markers include aspartate aminotransferase (AST) and alanine aminotransferase (ALT). [4] Viral markers include anti-HCV antibody and HCV-RNA quantification. Hepatocytes contain significant levels of AST and ALT. Elevated level of these enzymes can be determined if the liver is damaged. [5] Our aim of this study was as follows: (1) to correlate different biochemical markers and anti-HCV antibody with the value of HCV viral RNA A total of 238 patients were subjected to HCV viral load detection. Anti-HCV antibody and liver enzymes were tested with plain serum vacuumized containers. Ethylenediaminetetraacetic acid tubes were used to test HCV-RNA. Patients with hepatitis B virus (HBV)/HCV, HIV/HCV, HIV/HBV/HCV coinfection, and other forms of liver disease of nonviral etiology were excluded from the study.
Test methods
Liver enzymes (AST and ALT) were estimated by calorimetric method using VITROS 5600 instrument (Ortho Clinical Diagnostics, NJ, USA). Anti-HCV antibody detection was carried out using 3600 Ortho Immmunodiagnostic System and VITROS ECIQ Immmunodiagnostic System (Ortho Clinical Diagnostics, NJ, USA). HCV viral RNA extraction and quantification were done using Abbott m2000sp and m2000rt (Abbott Molecular Inc., USA) instrument. The RNA was extracted from the plasma using Abbott RNA isolation kit (Abbott Molecular Inc., USA) with a fully automated instrument m2000sp (Abbott Molecular Inc., USA.) which is based on magnetic particle technology. Extracted RNA was transferred to the Abbott m2000rt system (Abbott Molecular Inc., USA) for amplification. The fluorescent signal was detected by the Abbott m2000rt, which is proportional to the log of the HCV-RNA concentration present in the sample.
The reference values of our laboratory are 17-59 IU/L for AST and 21-72 IU/L for ALT. The reference values of anti-HCV antibody levels are 0.00-0.99 for nonreactive and ≥1.00 for reactive. The reference value for HCV-RNA was 12 -100 million IU/ ml.
Confirmation of diagnosis
The World Health Organization (WHO) recommends HCV serology testing of individuals who have a history of sensitization and/or are from the high-prevalence population (for example, patients with a history of jaundice). In seropositive cases, HCV-RNA testing is performed for the confirmation of diagnosis. [6] Monitoring of response to therapy There are different levels of virological response that has to be monitored from the time of initiation of therapy: (1) rapid virological response (RVR) is the absence of HCV-RNA at 4 weeks of treatment; (2) early virological response (EVR) defined as the absence of or ≥2 log reduction of HCV-RNA at week 12 of therapy; and (3) sustained virological response (SVR) is the absence of HCV-RNA by week 24 of treatment. [2, 6] Monitoring of response to treatment is required for predicting whether SVR has been achieved or not. SVR, in turn, helps the physician decide the discontinuation of antiviral therapy.
Statistical analysis
The ordinal data obtained were expressed in terms of mean and standard deviation. The analysis was performed using Microsoft Excel and SPSS software (version 24.0; IBM, Bengaluru, Karnataka, India).
Ethical approval
Patient consent was obtained for the diagnosis and treatment to the hospital. This was an observational study, and no additional sample was drawn for this study. All investigation, treatment, and monitoring were according to the current "Standard of Care."
Results

Demographics
Of 238 patients, 76% were male and 24% were female. The median age of the male patients was 47 ± 14 years and female patients was 48 ± 14 years, as shown in Figure 1 .
Association between hepatitis C virus viral load and liver enzymes
Significant positive correlation of HCV-RNA viral load was found with AST (P < 0.00001 and r -0.6227) and ALT (P < 0.0001 and r -0.4479). We did not found any correlation of HCV viral load with anti-HCV antibody (P < 0.00001 and r = −0.5266) [ Table 1 ].
Discussion
One hundred and eighty-four million people have chronic HCV infection globally with the majority of them from developing countries. [7] The WHO reports that 75% of HCV-infected individual develop chronic liver disease. Nearly 1.6% of chronic liver disease develop HCC having a mortality rate >80%. [8] Patients with HIV, patients on regular hemodialysis, those receiving multiple blood transfusions, organ transplant, sexually active adults with multiple partners, children with vertical transmission (3%-5%), [9] [10] [11] [12] injection drug users, those with tattooing, [13] [14] [15] [16] [17] and health-care workers are prone to the HCV infection. [4, 5] In our study, we assessed AST and ALT and found that they significantly relate to HCV viral load in patient samples. Mushtaq et al. [18] also found a significant positive relation between liver aminotransferase (AST and ALT) and viral load in the population of Pakistan. Puoti et al. [19] explained that abnormal levels of ALT were found in patients with HCV infection. Zechini et al. [20] also found a positive correlation between HCV viral load and different aminotransferases (AST and ALT). Ahmad et al. emphasize on a significant relationship of elevated level of liver enzymes with hepatitis C viral load in their study. [21] The association of viral load with liver enzymes has been reported in other countries, but this is possibly the first study reporting this in Indian patients.
It is considered that patients with chronic HCV infection have high HCV-RNA titer and abnormal level of ALT, and this is the basis of starting antiviral therapy and at later point in time, monitoring response to therapy. [22] For this regular, HCV-RNA quantification is usually done.
Conclusion
As India is a resource-constraint country, we are suggesting the use of liver enzymes (cost INR 300), ALT or AST, as a surrogate marker to monitor the response to therapy and predict RVR or EVR, which is otherwise, usually monitored by "viral load" test which is far more expensive (cost INR 6000). This suggestion of using liver enzyme instead of viral load tests, if adopted in the laboratory practice could help patients and bring down the overall cost of treatment. SVR would, however, be decided on the basis of viral load test only.
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